Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus

Chest

Volumn 117, Issue 6, 2000, Pages 1728-1733

  Simpson, Graham ^a   Roomes, David ^a   Heron, Mal ^b  

^a CAIRNS BASE HOSPITAL   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

Deoxyribonuclease; Empyema thoracis; Pus; Streptokinase; Viscosity

Indexed keywords

DORNASE ALFA; STREPTODORNASE; STREPTOKINASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EMPYEMA; HUMAN; PRIORITY JOURNAL; PUS; VISCOMETER; VISCOSITY;

EID: 0034118558     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.6.1728     Document Type: Article

References (19)

1. 1 Symbas PN. Chest drainage tubes. Surg Clin North Am 1989; 69:41-46
2. 2 Miller KS, Sahn SA. Chest tubes: indications, technique, management and complications. Chest 1987; 91:258-264
3. 3 Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal deoxyribonuclease on fibrinous, purulent and sanguineous pleural exudations. J Clin Invest 1949; 28:173-190
4. 4 Fraedrich G, Hoffman D, Effenhauser P, et al. Instillation of flbrinolytic enzymes in the treatment of pleural empyema. Thorac Cardiovasc Surg 1982; 30:36-38
5. 5 Temes RT, Follis F, Kessler RM, et al. Intrapleural fibrinolytics in management of empyema thoracis. Chest 1996; 110:102-106
6. 6 Laisaar T, Puttsepp E, Laisaar V. Early administration of intrapleural streptokinase in the treatment of multiloculated pleural effusions and pleural empyemas. Thorac Cardiovasc Surg 1996; 44:242-256
7. 7 Taylor RFH, Rubens MB, Pearson MC, et al. Intrapleural streptokinase in the management of empyema. Thorax 1994; 49:856-859
8. 8 Chin NK, Lim TK. Controlled trial of intrapleural streptokinase in the treatment of pleural empyema and complicated parapneumonic effusions. Chest 1997; 111:275-279
9. 9 Davies RJO, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997; 52:416-421
10. 10 Davies RJO, Gleeson FV. The diagnosis and management of pleural empyema. Curr Opin Pulm Med 1998; 4:185-190
11. 11 Bryant RE, Salmon CJ. Pleural empyema. Clin Infect Dis 1996; 22:747-764
12. 12 Sherry S, Tillett WS, Christenson LR. Presence and significance of deoxyribose nucleoprotein in the purulent pleural exudates of patients. Proc Soc Exp Biol Med 1948; 67:179-186
13. 13 Shak S, Capon DJ, Helniss R, et al. Recombinant human Dnasel reduces the viscosity of cystic fibrosis sputum. Proc Nad Acad Sci USA 1990; 87:9188-9192
14. 14 Simpson G, Roomes D. Thrombolytics and pleural empyema [letter]. Med J Aust 1998; 168:144
15. 15 Park JK, Kraus FC, Haaga JR. Fluid flow during percutaneous drainage procedures : an in vitro study of the effects of fluid viscosity, catheter size and adjunctive urokinase. Am J Roentgenol 1993; 160:165-169
16. 16 Martindale W. Extra pharmacopoeia. 30th ed. London, UK: Pharmacential Press, 1993; 1416-1417
17. 17 Hellgren L, Vincent J. Degradation and liquefaction effect of streptokinase-streptodornase and stabilised trypsin on necroses, crusts of fibrinoid, purulent exudate and clotted blood from leg ulcers. J Int Med Res 1977; 5:334-337
18. 18 Hellgren L. Cleansing properties of stabilised trypsin and streptokinase-streptodornase in necrotic leg ulcers. Eur J Clin Pharmacol 1983; 24:623-628
19. 19 Light RW. Pleural diseases. 3rd ed. Baltimore, MD: Williams & Wilkins, 1995; 142